THORN RUN PARTNERS for THE BIOSIMILARS FORUM
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Foreign entity interest: Merck KGaA, Novartis AG, Samsung Bioepis, Teva Pharmaceutical Industries Ltd., as identified on LD-1, are dues paying coalition members.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STUART CHAPMAN | Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee |
| ALEX DELPIZZO | Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee |
| THAYER SURETTE ROBERTS | — |
Health Issues HCR
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Foreign entity interest: Merck KGaA, Novartis AG, Samsung Bioepis, Teva Pharmaceutical Industries Ltd., as identified on LD-1, are dues paying coalition members.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STUART CHAPMAN | — |
| ALEX DELPIZZO | — |
| THAYER SURETTE ROBERTS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.